Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent split virion influenza vaccine
- Development stage
- Unknown
- Lead developer
- Changchun Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent split virion influenza vaccine is an inactivated vaccine designed to provide protection against four different influenza virus strains: two influenza A subtypes (typically H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The 'split virion' technology involves disrupting the virus particles with detergents, which maintains the immunogenicity of the hemagglutinin and neuraminidase proteins while reducing the risk of reactogenicity compared to whole-virus vaccines. This vaccine type is a standard for seasonal influenza prevention and is developed by various manufacturers, including the Changchun Institute of Biological Products and Jiangsu Jindike Biotechnology. It is typically administered as a single intramuscular dose to adults and children to stimulate the production of neutralizing antibodies against the hemagglutinin protein of the included strains.
- Brand names
- Jinfuwei
- Other names
- quadrivalent inactivated influenza vaccine (split virion)QIVquadrivalent split-virion flu vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent split virion influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent split virion influenza vaccine.